Cigna

Does Cigna cover Zepbound?

Quick answer · Weight Loss

Cigna covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
  • ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 2, 2026. Policy effective April 15, 2026. Source: cnf_684_coveragepositioncriteria_weight_loss_glp1_agonists_pa.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Cigna requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, knee_osteoarthritis, asthma, COPD, MASLD/NAFLD, PCOS, and CAD)
  • 3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial Approval - Adult Weight Loss (BMI >= 30)

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Initial Approval - Adult Weight Loss (BMI >= 27 with comorbidity)

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 27 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Plus any one of:

  • At baseline or currently: hypertension
  • At baseline or currently: type 2 diabetes
  • At baseline or currently: dyslipidemia
  • At baseline or currently: obstructive sleep apnea
  • At baseline or currently: cardiovascular disease
  • At baseline or currently: knee osteoarthritis
  • At baseline or currently: asthma
  • At baseline or currently: COPD
  • At baseline or currently: MASLD/NAFLD
  • At baseline or currently: polycystic ovarian syndrome
  • At baseline or currently: coronary artery disease

Continuation - Adult Weight Loss

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 OR (BMI >= 27 kg/m2 with qualifying comorbidity) (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has lost >= 5% of baseline body weight
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Patient has completed >= 8 months of initial therapy

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2, or >= 27 kg/m2 with qualifying comorbidity, prior to any GLP-1 or GLP-1/GIP agonist)
  • Documentation of at least 3-month trial of behavioral modification and dietary restriction (initial therapy)
  • Documentation of qualifying weight-related comorbidity if baseline BMI 27-29.9 kg/m2
  • Documentation of >= 5% baseline body weight loss (continuation)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Must have lost >= 5% of baseline body weight (baseline = prior to any GLP-1 or GLP-1/GIP agonist). Ongoing behavioral modification and reduced-calorie diet required. BMI threshold re-verified at continuation; 3-month lifestyle program not re-checked. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists is not covered
  • Any use not meeting FDA-approved indications or criteria above is not medically necessary

Policy note: Zepbound weight loss indication is for adults only (age >= 18); no pediatric indication for weight loss. Initial approval is 8 months; continuation is 1 year. Baseline BMI is defined as prior to any GLP-1 or GLP-1/GIP agonist (not just prior to Zepbound).

Policy effective April 15, 2026 · verified June 2, 2026 · source: cnf_684_coveragepositioncriteria_weight_loss_glp1_agonists_pa.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, knee_osteoarthritis, asthma, COPD, MASLD/NAFLD, PCOS, and CAD)
  • 3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial Approval - Adult Weight Loss (BMI >= 30)

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Initial Approval - Adult Weight Loss (BMI >= 27 with comorbidity)

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 27 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Plus any one of:

  • At baseline or currently: hypertension
  • At baseline or currently: type 2 diabetes
  • At baseline or currently: dyslipidemia
  • At baseline or currently: obstructive sleep apnea
  • At baseline or currently: cardiovascular disease
  • At baseline or currently: knee osteoarthritis
  • At baseline or currently: asthma
  • At baseline or currently: COPD
  • At baseline or currently: MASLD/NAFLD
  • At baseline or currently: polycystic ovarian syndrome
  • At baseline or currently: coronary artery disease

Continuation - Adult Weight Loss

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 OR (BMI >= 27 kg/m2 with qualifying comorbidity) (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has lost >= 5% of baseline body weight
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet
  • Patient has completed >= 8 months of initial therapy

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2, or >= 27 kg/m2 with qualifying comorbidity, prior to any GLP-1 or GLP-1/GIP agonist)
  • Documentation of at least 3-month trial of behavioral modification and dietary restriction (initial therapy)
  • Documentation of qualifying weight-related comorbidity if baseline BMI 27-29.9 kg/m2
  • Documentation of >= 5% baseline body weight loss (continuation)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Must have lost >= 5% of baseline body weight (baseline = prior to any GLP-1 or GLP-1/GIP agonist). Ongoing behavioral modification and reduced-calorie diet required. BMI threshold re-verified at continuation; 3-month lifestyle program not re-checked. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists is not covered
  • Any use not meeting FDA-approved indications or criteria above is not medically necessary

Policy note: Zepbound weight loss indication is for adults only (age >= 18); no pediatric indication for weight loss. Initial approval is 8 months; continuation is 1 year. Baseline BMI is defined as prior to any GLP-1 or GLP-1/GIP agonist (not just prior to Zepbound).

Policy effective April 15, 2026 · verified June 2, 2026 · source: cnf_684_coveragepositioncriteria_weight_loss_glp1_agonists_pa.pdf

Zepbound for Osa

What Cigna requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Initial Approval - Moderate to Severe OSA with Obesity

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Sleep study showing diagnosis of moderate to severe OSA
  • Sleep study showing apnea-hypopnea index (AHI) >= 15 events per hour
  • Patient does NOT have central sleep apnea
  • Patient does NOT have Cheyne Stokes respiration
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Continuation - Moderate to Severe OSA with Obesity

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has completed >= 1 year of therapy with Zepbound
  • Patient has lost >= 10% of baseline body weight
  • Prescriber attests patient has stability in OSA signs or symptoms
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2, prior to any GLP-1 or GLP-1/GIP agonist)
  • Sleep study results documenting moderate to severe OSA diagnosis
  • Sleep study results documenting AHI >= 15 events per hour
  • Confirmation patient does not have central sleep apnea or Cheyne Stokes respiration
  • Documentation of >= 10% baseline body weight loss (continuation)
  • Prescriber attestation of stability in OSA signs or symptoms (continuation)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 10% weight loss from the starting weight and Continuation requires: >= 10% baseline body weight loss AND prescriber attestation of stability in OSA signs or symptoms (e.g., snoring, excessive daytime sleepiness, fatigue). Patient must have completed >= 1 year of initial therapy. PAP therapy status is NOT re-evaluated at continuation. OSA AHI is not re-measured at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Central sleep apnea is excluded
  • Cheyne Stokes respiration is excluded
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists is not covered

Policy note: PAP/CPAP trial is NOT required prior to approval; patients using PAP therapy or not using PAP therapy are both eligible. Sleep study must document AHI >= 15 events/hour but there is no specific timeframe requirement for how recent the sleep study must be (a prior requirement for within 1 year was removed in May 2025). Moderate OSA = AHI >= 15; Severe OSA = AHI >= 30. Continuation requires >= 10% body weight loss (higher than the 5% threshold for weight loss indication). No pediatric indication for OSA.

Policy effective April 15, 2026 · verified June 2, 2026 · source: cnf_684_coveragepositioncriteria_weight_loss_glp1_agonists_pa.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Initial Approval - Moderate to Severe OSA with Obesity

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Sleep study showing diagnosis of moderate to severe OSA
  • Sleep study showing apnea-hypopnea index (AHI) >= 15 events per hour
  • Patient does NOT have central sleep apnea
  • Patient does NOT have Cheyne Stokes respiration
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Continuation - Moderate to Severe OSA with Obesity

All of:

  • Patient is >= 18 years of age
  • Baseline BMI >= 30 kg/m2 (prior to any GLP-1 or GLP-1/GIP agonist)
  • Patient has completed >= 1 year of therapy with Zepbound
  • Patient has lost >= 10% of baseline body weight
  • Prescriber attests patient has stability in OSA signs or symptoms
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2, prior to any GLP-1 or GLP-1/GIP agonist)
  • Sleep study results documenting moderate to severe OSA diagnosis
  • Sleep study results documenting AHI >= 15 events per hour
  • Confirmation patient does not have central sleep apnea or Cheyne Stokes respiration
  • Documentation of >= 10% baseline body weight loss (continuation)
  • Prescriber attestation of stability in OSA signs or symptoms (continuation)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 10% weight loss from the starting weight and Continuation requires: >= 10% baseline body weight loss AND prescriber attestation of stability in OSA signs or symptoms (e.g., snoring, excessive daytime sleepiness, fatigue). Patient must have completed >= 1 year of initial therapy. PAP therapy status is NOT re-evaluated at continuation. OSA AHI is not re-measured at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Central sleep apnea is excluded
  • Cheyne Stokes respiration is excluded
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists is not covered

Policy note: PAP/CPAP trial is NOT required prior to approval; patients using PAP therapy or not using PAP therapy are both eligible. Sleep study must document AHI >= 15 events/hour but there is no specific timeframe requirement for how recent the sleep study must be (a prior requirement for within 1 year was removed in May 2025). Moderate OSA = AHI >= 15; Severe OSA = AHI >= 30. Continuation requires >= 10% body weight loss (higher than the 5% threshold for weight loss indication). No pediatric indication for OSA.

Policy effective April 15, 2026 · verified June 2, 2026 · source: cnf_684_coveragepositioncriteria_weight_loss_glp1_agonists_pa.pdf

Why Zepbound requests get denied by Cigna

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Cigna cover Zepbound?
Cigna covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under Cigna?
For weight loss on Employer / Commercial Insurance plans, Cigna requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with Cigna?
Initial approvals last 8 months, and renewals are granted in 12-month periods.
What does Cigna require to renew Zepbound?
At least 5% weight loss from the starting weight and Must have lost >= 5% of baseline body weight (baseline = prior to any GLP-1 or GLP-1/GIP agonist). Ongoing behavioral modification and reduced-calorie diet required. BMI threshold re-verified at continuation; 3-month lifestyle program not re-checked.
How current is this information?
This page reflects Cigna's written policy as of April 15, 2026, last verified against the source document on June 2, 2026.

Other medications under Cigna

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Cigna's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.